Abstract:Abstract BACKGROUND AND AIMS Cardiovascular disease (CVD) is the leading cause of death among patients with chronic kidney disease (CKD). In addition to diabetes, hypertension, dyslipidaemia and inflammation, vascular calcification and its severity have long been recognized as a major factor in the development of CVD in patients with CKD. CKD favours gut dysbiosis, and this dysbiosis may contribute to the aggravation of CVD, inflammation, and vascular calcification in CKD. Therefore, our aim was to study the potential interconnection between vascular calcification, mortality risk, and the gut microbiome in CKD patients on peritoneal dialysis (PD). METHOD A group of 44 CKD patients on PD was evaluated concerning major inflammatory markers and key players of CKD-mineral bone disorder. Vascular calcification severity was assessed by the Adragao score, and all-cause mortality risk was assessed using the Charlson comorbidity index. Gut microbiome profile was obtained by sequencing the V3–V4 region of 16S rRNA. RESULTS The global mean of the Adragao score of our CKD-PD patients was 2.98 ± 2.74, including 26.1% with no vascular calcification (Adragao score = 0), 30.4% with moderate vascular calcification (Adragao score of 1 or 2), and 39.1% presenting severe vascular calcification (Adragao score higher than 2). When comparing CKD-PD patients with moderate or severe vascular calcification with CKD-PD patients with no vascular calcification, we found statistically significant differences regarding age (47.7 ± 11.5 versus 59.4 ± 8.8; P < 0.01), sex (% male 33.3% versus 78.1%; P = 0.011), total Kt/V (urea) (2.6 ± 0.6 versus 2.1 ± 0.4; P = 0.04) and history of diabetes mellitus (8.3% versus 48.8%; P = 0.035). No differences were found regarding the expression of inflammation markers between the two groups. When vascular calcification severity was correlated with all-cause mortality risk scored by the Charlson comorbidity index, we observed a positive significant correlation between these two factors (Spearman correlation, correlation coefficient = 0.538; P < 0.001). When comparing PD patients with and without vascular calcification, no significant differences were found regarding gut microbiome profile. Nonetheless, relative changes of specific taxa were observed, namely regarding Coprobacter, Coprococcus 3, Lactobacillus and Eubacterium eligens group in the gut microbiome. Among these taxonomic differences, patients with different Charlson comorbidity index values also demonstrated changes in the Eubacterium eligens group in the gut microbiome. The Adragao score and the Charlson index were positively correlated. CONCLUSION There is an association between vascular calcification and mortality risk in CKD patients on PD. We have found small differences in some specific taxa when comparing the gut microbiomes of CKD-PD patients with and without vascular calcification. Future studies exploring the role of these bacterial groups in the increased risk of vascular calcification, mortality and CVD in CKD-PD patients are of extreme relevance to ensure the health and well-being of these patients.

Evaluation of MicroRNA 145 and MicroRNA 155 as Markers of Cardiovascular Risk in Chronic Kidney Disease

Predicting Cardiovascular Mortality in Chronic Kidney Disease (CKD) Patients.

Circulating microRNAs as biomarkers of chronic kidney disease and its association with renal and cardiovascular outcomes in non-dialysis patients

Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease

MicroRNAs as Potential Biomarkers for the Diagnosis of Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Cardiac Magnetic Resonance Assessment of Cardiac Function Across Chronic Kidney Disease Stages

Relations Between Markers of Renal Function, Coronary Risk Factors and the Occurrence and Severity of Coronary Artery Disease

Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder

Arginine Metabolites as Biomarkers of Myocardial Ischaemia, Assessed with Cardiac Magnetic Resonance Imaging in Chronic Kidney Disease

Massive analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease

Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease

The Role of Prognostic and Predictive Biomarkers for Assessing Cardiovascular Risk in Chronic Kidney Disease Patients

Circulating miRNA 122-5p Expression Predicts Mortality and Cardiovascular Events in Chronic Hemodialysis Patients: A Multicentric, Pilot, Prospective Study

Gut Microbial Product Predicts Cardiovascular Risk in Chronic Kidney Disease Patients

Diagnosis of cardiovascular disease in patients with chronic kidney disease

Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease

Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study

Role of predictable biomarkers in early detection of cardiovascular events in Chronic Kidney Disease III and IV

MO737: Vascular Calcification and the Gut Microbiome in Chronic Kidney Disease Patients on Peritoneal Dialysis

Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis

MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application